Department of Urology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26 Shengli Street, Wuhan, 430014, China.
Ir J Med Sci. 2024 Feb;193(1):85-93. doi: 10.1007/s11845-023-03461-z. Epub 2023 Jul 31.
Chaperonin-containing tailless complex polypeptide 1 subunit 6A (CCT6A) involves several solid cancers' development and progression, while its clinical utility in prostate cancer management is rarely revealed. Consequently, the present study intended to investigate the linkage of CCT6A with disease features, treatment information, and prognosis of surgical prostate cancer patients.
CCT6A in 220 surgical prostate cancer patients was determined via immunohistochemistry. Additionally, survival analyses on data from the public databases were performed to validate the prognostic value of CCT6A further.
CCT6A expression was upregulated in tumor tissue than in adjacent tissue (P < 0.001). Increased CCT6A was related to elevated Gleason score (P < 0.001) and pathological T stage (P = 0.029). CCT6A was increased in patients with positive surgical margin status (vs. negative) (P = 0.029) and patients with adjuvant external-beam radiation therapy (vs. no) (P = 0.001). Concerning the prognostic value, high tumor CCT6A was linked with shortened disease-free survival (DFS) (P = 0.009), which was also validated through further Cox's proportional hazard regression model analyses (hazard ratio: 2.695, 95% CI: 1.086-6.683, P = 0.032), whereas CCT6A was not correlated with overall survival (OS) (P > 0.050). Additionally, the Gene Expression Profiling Interactive Analysis database indicated that high tumor CCT6A was related to shortened DFS (P = 0.036), but it was not associated with OS (P > 0.050); meanwhile, the Human Protein Atlas database suggested that high tumor CCT6A was linked with reduced OS (P = 0.048).
Tumor CCT6A high expression correlates with the elevated Gleason score, pathological T stage, and shortened DFS in surgical prostate cancer patients.
含伴侣素的无尾复合物多肽 1 亚基 6A（CCT6A）参与多种实体瘤的发生和发展，但其在前列腺癌管理中的临床应用鲜有报道。因此，本研究旨在探讨 CCT6A 与手术治疗前列腺癌患者疾病特征、治疗信息和预后的相关性。
采用免疫组织化学法检测 220 例手术治疗前列腺癌患者的 CCT6A。此外，还对公共数据库中的数据进行了生存分析，以进一步验证 CCT6A 的预后价值。
CCT6A 在肿瘤组织中的表达高于邻近组织（P<0.001）。CCT6A 的增加与较高的 Gleason 评分（P<0.001）和病理 T 分期（P=0.029）相关。CCT6A 在切缘阳性（vs. 阴性）（P=0.029）和接受辅助外照射治疗（vs. 未接受）（P=0.001）的患者中增加。就预后价值而言，肿瘤 CCT6A 高与无病生存期（DFS）缩短相关（P=0.009），这也通过进一步的 Cox 比例风险回归模型分析得到验证（危险比：2.695，95%置信区间：1.086-6.683，P=0.032），而 CCT6A 与总生存期（OS）无关（P>0.050）。此外，基因表达谱交互分析数据库表明，肿瘤 CCT6A 高与 DFS 缩短相关（P=0.036），但与 OS 无关（P>0.050）；同时，人蛋白质图谱数据库表明，肿瘤 CCT6A 高与 OS 降低相关（P=0.048）。
手术治疗的前列腺癌患者中，肿瘤 CCT6A 高表达与 Gleason 评分升高、病理 T 分期和 DFS 缩短相关。
